Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. News
  7. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 01/25
10.44 HKD   -8.10%
01/10JW Therapeutics Appoints Immunotherapy Expert as Chief Scientific Officer
MT
01/09JW Therapeutics Announces Management Appointments
CI
2021JW Therapeutics Grants Share Options to Certain Employees
MT
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

09/27/2021 | 08:00am EST

JW Therapeutics announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in treating relapsed or refractory multiple myeloma (R/R MM). Multiple myeloma (MM) is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. Although treatment may result in remission, unfortunately, patients will most likely relapse. While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections. Patients who relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, have poor prognoses and few treatment options available. As a result, there is a significant unmet need for patients with R/R MM.


ę S&P Capital IQ 2021
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
01/10JW Therapeutics Appoints Immunotherapy Expert as Chief Scientific Officer
MT
01/09JW Therapeutics Announces Management Appointments
CI
2021JW Therapeutics Grants Share Options to Certain Employees
MT
2021JW Therapeutics Co. Ltd Announces Executive Changes
CI
2021JW Therapeutics Presents Immunotherapy Study Findings at US Conference; Shares Jump 4%
MT
2021JW Therapeutics Co. Ltd Announces Board and Committee Changes
CI
2021JW CAYMAN THERAPEUTICS : Therapeutics Awards 7 Million Share Options, Nearly 5 Million Res..
MT
2021JW (CAYMAN) THERAPEUTICS : to Start Clinical Trials of Multiple Myeloma Treatment in China
MT
2021JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
CI
2021JW CAYMAN THERAPEUTICS : Therapeutics Says Immunotherapy Shows Long-Term Efficacy in Large..
MT
More news
Financials
Sales 2021 64,6 M 10,2 M 10,2 M
Net income 2021 -603 M -95,4 M -95,4 M
Net cash 2021 1 836 M 290 M 290 M
P/E ratio 2021 -6,04x
Yield 2021 -
Capitalization 3 458 M 547 M 547 M
EV / Sales 2021 25,1x
EV / Sales 2022 7,52x
Nbr of Employees 477
Free-Float -
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,48 CNY
Average target price 20,67 CNY
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Shaun Paul Cordoba Chief Scientific Officer
Chi Shing Li Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-22.32%547
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796